Elegen

Elegen Corporation is a pioneering biotechnology company headquartered in San Carlos, California, focused on advancing synthetic biology through innovative DNA synthesis technologies. The company is recognized for its transformative ENFINIA™ technology, which enables cell-free DNA synthesis that delivers long, complex linear DNA rapidly without compromising accuracy or quality. Elegen's capabilities range from producing linear DNA sequences up to 7,000 base pairs in just 6 to 8 business days, to extensive plasmid DNA synthesis accommodating lengths of up to 15,000 base pairs within a swift 10-day timeframe.

Founded in 2017 by Dr. Matthew Hill, Elegen has positioned itself at the forefront of the bioeconomy, addressing critical challenges in various sectors, including genetic medicine, food security, and biomanufacturing. Operating in a stealth mode for the past several years, it has secured support from prominent investors, signaling strong market confidence in its innovative approach. Elegen's mission is clear: to facilitate rapid development cycles for researchers and companies engaged in synthetic biology by providing high-accuracy, scalable solutions that streamline workflows and significantly reduce lead times. With a commitment to innovation and quality, Elegen is setting new standards in DNA synthesis, responding to the demands of next-generation biotechnological applications and the growing need for advanced genetic materials.